Prolia approved for postmenopausal osteoporosis - ONA
Links shared publicly online about this topic.
- 1,123total visits
Prolia approved for postmenopausal osteoporosis - ONA
View full resource at oncologynurseadvisor.com
Tags: Fracture, Osteoporosis, Osteoporosis Medication, Women's Health, FDA, Prolia, Amgen
Most Recently Shared on June 2, 2010 at 3:00 pm By:
Prolia approved for postmenopausal osteoporosis http://goo.gl/fb/bGLvd
Generic Boniva Approved for Osteoporosis --Doctors Lounge
doctorslounge.com — “Generic Boniva Approved for Osteoporosis --Doctors Lounge” View full resource at doctorslounge.com
Most Recently Shared on March 19, 2012 at 9:24 pm By:
Generic Boniva Approved for Osteoporosis: In postmenopausal women http://t.co/zYKwBX7O
EffRx receives FDA approval for BINOSTO to treat osteoporosis
news-medical.net — “EffRx Pharmaceuticals SA today announced that the U.S. Food and Drug Administration (FDA) has approved BINOSTO (alendronate sodium) Effervescent Tablets, previously known as EX101, for the treatment of osteoporosis in postmenopausal women, and as a treatment to increase bone mass in men with osteoporosis. EffRx anticipates that BINOSTO will be commercially available in the United States in the third quarter of 2012.” View full resource at news-medical.net
Most Recently Shared on March 15, 2012 at 4:26 am By:
News-Medical.Net Health News and Oncology
Oncology News: EffRx receives FDA approval for BINOSTO to treat osteoporosis: EffRx Pharmaceuticals SA today ann... http://t.co/oNs9QvFc
FDA clears Amgen bone drug for cancer patients | Reuters
reuters.com — “WASHINGTON (Reuters) - U.S. drug regulators approved two new uses for Amgen Inc's osteoporosis drug Prolia, allowing it to be used for bone loss associated with certain cancer treatments.The Food and” View full resource at reuters.com
Most Recently Shared on September 19, 2011 at 7:37 pm By:
Hisham Rana, MD Doctor and Physician
News: U.S. FDA clears Amgen bone drug for cancer patients http://t.co/MR0ALdM9 - #health #pharma
Prolia (Denosumab) Maintains Menopausal Women's Bone Density For Over Eight Years
medicalnewstoday.com — “Postmenopausal females with osteoporosis or low bone mass who are on Prolia (denosumab) treatment were found to have continued increase in BMD (bone mineral density) for up to eight years, Amgen a” View full resource at medicalnewstoday.com
Most Recently Shared on September 19, 2011 at 6:05 am By:
Prolia (Denosumab) Maintains Menopausal Women's Bone Density For Over Eight Years http://mnt.to/3ZJM #healthnews
Amgen Highlights Data To Be Presented At American Society For Bone And Mineral Research Meeting - QualityPoint Technologies
qualitypointtech.net — “Amgen (NASDAQ: AMGN) announced that it will present data from several Prolia® (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in San Diego, Calif. from Sept. 16-20, 2011.” View full resource at qualitypointtech.net
Most Recently Shared on August 20, 2011 at 11:45 am By:
Amgen Highlights Data To Be Presented At American Society For Bone And Mineral Research Meeting: Amgen (NASDAQ: AM... http://t.co/y8KRr3M
New Analyses Of Prolia(R) (Denosumab) Pivotal Phase 3 Trials Reinforce Potential Advantages Over Standard Of Care
medicalnewstoday.com — “Amgen today announced new long-term data showing that during the fourth and fifth years of Prolia® (denosumab) treatment, postmenopausal women with osteoporosis receiving Prolia continued with” View full resource at medicalnewstoday.com
Most Recently Shared on March 24, 2011 at 4:05 pm By:
New Analyses Of Prolia(R) (Denosumab) Pivotal Phase 3 Trials Reinforce Potential Advantages Over Standard Of Care http://mnt.to/3SHy
Drug reduces gum disease, risk of osteoporosis, heart disease in women
physorg.com — “(PhysOrg.com) -- New research has shown that a federally approved pharmaceutical for treating periodontal disease also significantly reduces risk of osteoporosis and cardiovascular disease in postmenopausal women.” View full resource at physorg.com
Most Recently Shared on March 10, 2011 at 2:59 pm By:
PhysOrg Health News Health News
Drug reduces gum disease, risk of osteoporosis, heart disease in women http://tw.physorg.com/218973319
NHS 'will help beat osteoporosis' with cheap six-monthly jabs | Mail Online
dailymail.co.uk — “Post-menopausal women at increased risk of fractures should be treated with Prolia if other treatments are unsuitable, says the drug rationing body Nice.” View full resource at dailymail.co.uk
Most Recently Shared on November 5, 2010 at 11:50 am By:
Physician Assistants Health News Feed
NHS 'will help beat osteoporosis' with denosumab, Amgen monoclonal http://tinyurl.com/2fsclrs
Pfizer Bone Drug Reduces Breast Cancer Risk in Older Women - Bloomberg
bloomberg.com — “Pfizer Inc.'s Fablyn, the bone drug that failed to win U.S. approval amid safety questions, reduced the risk of breast cancer and fractures in postmenopausal women with osteoporosis, a company-sponsored study found.” View full resource at bloomberg.com
Most Recently Shared on November 4, 2010 at 9:21 pm By:
Men For A Cause (TM) Health Organization
Pfizer Bone Drug Reduces Breast Cancer Risk in Older Women http://ping.fm/Z6Ucd
Warner Chilcott Announces FDA Approval of Atelvia - Next Generation Actonel
drugs.com — “Atelvia (risedronate sodium) is used to treat postmenopausal osteoporosis. Includes Atelvia side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on October 12, 2010 at 1:23 am By:
Warner Chilcott Announces FDA Approval of Atelvia - Next Generation Actonel - http://bit.ly/azU3ZW
Warner Chilcott Announces FDA Approval of Atelvia - Next Generation Actonel
drugs.com — “Atelvia (risedronate sodium) is used to treat postmenopausal osteoporosis. Includes Atelvia side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on October 12, 2010 at 1:06 am By:
Drugs and Devices OW OW Health
Warner Chilcott Announces FDA Approval of Atelvia - Next Generation Actonel: ARDEE, Ireland, October 11, 2010... http://bit.ly/cdu7sZ #drug
FDA approves Atelvia for osteoporosis - MPR
empr.com — “Warner Chilcott announced that the FDA has approved Atelvia (risedronate sodium delayed-release tablets) for the treatment of postmenopausal osteoporosis.” View full resource at empr.com
Most Recently Shared on October 11, 2010 at 9:11 pm By:
MPR News: FDA approves Atelvia for osteoporosis: Warner Chilcott announced that the FDA has approved Atelvia (rise... http://bit.ly/bMI8U9
FDA approves Warner Chilcott's ACTONEL for postmenopausal osteoporosis
news-medical.net — “Warner Chilcott plc today announced that the United States Food and Drug Administration (FDA) has approved its next generation ACTONEL® (risedronate sodium) product for the treatment of postmenopausal osteoporosis in the United States. The product will be marketed as ATELVIA" (risedronate sodium) delayed-release tablets.” View full resource at news-medical.net
Most Recently Shared on October 11, 2010 at 4:09 pm By:
Osteoporosis News: FDA approves Warner Chilcott's ACTONEL for postmenopausal osteoporosis: Warner Chilcott plc tod... http://bit.ly/a4v3yc
Physician's Weekly Article - Battling Osteoporosis When Fracture Risks Are High
physweeklyarchives.com — “Physician's Weekly, your source for medical news, information on new drugs and devices, clinical updates, CME accreditation for radiology, emergency medicine, pediatrics, mammography, and anesthesia .” View full resource at physweeklyarchives.com
Most Recently Shared on August 26, 2010 at 9:29 pm By:
Battling Osteoporosis When Fracture Risks Are High - Denosumab (Prolia, Amgen, Inc.) has been approved by the FDA to... http://ow.ly/18JYcd
FDA Approves Amgen's Prolia(TM) (Denosumab) For Treatment Of Postmenopausal Women With Osteoporosis At High Risk For Fracture
medicalnewstoday.com — “Amgen Inc. (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high ris” View full resource at medicalnewstoday.com
Most Recently Shared on August 8, 2010 at 11:36 am By:
Women's Health Line Health Site
FDA Approves Amgen's Prolia(TM) (Denosumab) For Treatment Of Postmenopausal Women With Osteoporosis At... http://sns.ly/zJe48 #womenshealth
Advertisement
